Recent progress on the US regulatory front is generating renewed interest in device-based glaucoma therapies, which potentially could grow to a multibillion-dollar industry. The list of companies targeting this space continues to expand, as does the variety of potential device-based solutions: the current pipeline includes several innovative and less invasive products and technologies designed to improve surgical outcomes, a growing number of advanced drug-delivery inserts to address the patient noncompliance issue that is so common in this arena, and some unique patient monitoring devices.
Fertility Focus has two products that it says address 85% of the causes of female infertility, and assist in earlier diagnosis and treatment: the OvuSense home-use ovulation detection and fertile period predictor and the FertiloScope, a trans-vaginal laparoscopic instrument that is designed to diagnose and treat the main physical causes of female infertility in one minimally invasive outpatient procedure.
Once beyond reproach, knee replacement surgeries are getting a long, hard look by surgeons, researchers, and companies trying to determine whether success rates that exceed 90% can be improved upon by using customized implants or surgical robots.
An unprecedented release of data by the agency highlights vast differences across the country between what hospitals charge for different procedures, but the disparities by and large don’t reflect actual hospital costs.
Although Edwards is the pioneer and market leader in TAVR, there is no shortage of competitors – in both the aortic and mitral valve segments – developing next-generation devices who would be happy with a fraction of this potential multibillion-dollar opportunity.
Call it digital health, mobile health, connected health, or information-enabled care delivery, in health care there is a new convergence of wireless sensing technologies, tablets, personalized medicine, cloud-based computing, and novel business models, and it all goes under the rubric of health care efficiency. Going forward, the latter will be the driver of Aberdare Venture Capital’s investment strategy, and in April, the VC made an announcement that signaled its whole-hearted commitment to the space.
Why are European physicians so far ahead of the curve when it comes to innovative clinical practice and so far behind when it comes to creating companies? Interventional cardiologist and serial entrepreneur Martin Rothman offers some answers.
Industry representatives, health care providers, patients and caregivers gathered April 29-30 to discuss CDRH labeling activities and the agency’s ideas for the future.
The current technologies for diagnosing spinal disease don’t consistently deliver what’s required of any medical diagnostic: good predictive value, high specificity, sensitivity, validity, reproducibility, and safety. This is a gap that several young, innovative companies have set out to fill.
Neuromodulation is one of the largest and fastest growing segments of the worldwide medical device market, with global revenues expected to reach $6 billion by 2020; as a result, the number of products in the neuromodulation pipeline is exploding. New and improved technologies will permit deeper penetration of neuromodulation therapies into existing patient groups as well as expansion of the market to new patient populations that could eventually number in the multi-millions.
